BG108268A - Pyrazolopyrimidines as therapeutic agents - Google Patents
Pyrazolopyrimidines as therapeutic agentsInfo
- Publication number
- BG108268A BG108268A BG108268A BG10826803A BG108268A BG 108268 A BG108268 A BG 108268A BG 108268 A BG108268 A BG 108268A BG 10826803 A BG10826803 A BG 10826803A BG 108268 A BG108268 A BG 108268A
- Authority
- BG
- Bulgaria
- Prior art keywords
- pyrazolopyrimidines
- therapeutic agents
- prodrugs
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27804701P | 2001-03-22 | 2001-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108268A true BG108268A (en) | 2005-04-30 |
Family
ID=23063472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108268A BG108268A (en) | 2001-03-22 | 2003-10-14 | Pyrazolopyrimidines as therapeutic agents |
Country Status (21)
Country | Link |
---|---|
US (1) | US7332497B2 (xx) |
EP (1) | EP1379528A4 (xx) |
JP (1) | JP4319412B2 (xx) |
KR (1) | KR20030088114A (xx) |
CN (1) | CN101426792A (xx) |
BG (1) | BG108268A (xx) |
BR (1) | BR0205890A (xx) |
CA (1) | CA2440714C (xx) |
CO (1) | CO5570669A2 (xx) |
CZ (1) | CZ20032837A3 (xx) |
EC (1) | ECSP034773A (xx) |
HU (1) | HUP0400267A2 (xx) |
IL (1) | IL157640A0 (xx) |
MX (1) | MXPA03008560A (xx) |
NO (1) | NO20034177L (xx) |
PE (1) | PE20030047A1 (xx) |
PL (1) | PL363946A1 (xx) |
SK (1) | SK13122003A3 (xx) |
UY (1) | UY27222A1 (xx) |
WO (1) | WO2002076986A1 (xx) |
ZA (1) | ZA200306887B (xx) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
AU8473401A (en) * | 2000-08-04 | 2002-02-18 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
CA2444632A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
CA2444624A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
CN1898240B (zh) * | 2003-10-15 | 2011-08-03 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
BRPI0509576A (pt) | 2004-04-02 | 2007-05-29 | Osi Pharm Inc | composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica |
US20080287405A1 (en) * | 2004-05-14 | 2008-11-20 | Thannickal Victor J | Compositions and Methods Relating to Protein Kinase Inhibitors |
MXPA06013250A (es) * | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
NZ571182A (en) * | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
DK2099442T3 (en) * | 2006-12-26 | 2015-02-16 | Pharmacyclics Inc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
MX2009010284A (es) * | 2007-03-28 | 2010-01-29 | Pharmacyclics Inc | Inhibidores de la tirosina-cinasa de bruton. |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
US7998688B2 (en) * | 2008-03-07 | 2011-08-16 | OSI Pharmaceuticals, LLC | Inhibition of EMT induction in tumor cells by anti-cancer agents |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
US20100101977A1 (en) * | 2008-06-05 | 2010-04-29 | United Comb & Novelty Corporation | Stackable Packaging For Lipped Containers |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
MX2011000661A (es) * | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
CN103333157A (zh) | 2008-09-02 | 2013-10-02 | 诺瓦提斯公司 | 作为激酶抑制剂的吡啶甲酰胺衍生物 |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
ES2570429T3 (es) * | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
EP2528919B1 (en) * | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
CN102906074A (zh) * | 2010-05-24 | 2013-01-30 | 东亚荣养株式会社 | 稠合咪唑衍生物 |
IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
AU2011276955B2 (en) * | 2010-07-09 | 2014-11-06 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
WO2012097196A1 (en) * | 2011-01-12 | 2012-07-19 | Acea Biosciences Inc. | Pyrazolopyrimidine derivatives and uses as anticancer agents |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9173883B2 (en) | 2012-05-21 | 2015-11-03 | Novartis Ag | Ring-substituted N-pyridinyl amides as kinase inhibitors |
UA114421C2 (uk) | 2012-06-04 | 2017-06-12 | Фармасайклікс Ллс | Кристалічна форма інгібітору тирозинкінази брутона |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
EP2878601B1 (en) * | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
PT2892900T (pt) * | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ire1の調節 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) * | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
EP2999696B1 (en) | 2013-05-20 | 2017-08-16 | University Of Washington Through Its Center For Commercialization | 5-aminopyrazole-4-carboxamide inhibitors of cdpk1 from t. gondii and c. parvum |
US10562912B2 (en) * | 2013-06-05 | 2020-02-18 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
JP2016538270A (ja) | 2013-10-25 | 2016-12-08 | ファーマサイクリックス エルエルシー | 移植片対宿主病を処置し予防する方法 |
EP3107544B1 (en) | 2014-02-21 | 2020-10-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
BR112017002231A2 (pt) | 2014-08-07 | 2018-07-17 | Pharmacyclics Llc | novas formulações de um inibidor de tirosina cinase de bruton |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10196397B2 (en) | 2014-11-19 | 2019-02-05 | Sun Pharmaceutical Industries Limited | Process for the preparation of ibrutinib |
CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
GB201508747D0 (en) * | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
MX2018002916A (es) * | 2015-09-09 | 2018-09-12 | C Lau Warren | Metodos, composiciones y usos de nuevos inhibidores de fyn quinasa. |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
TW201806953A (zh) * | 2016-04-26 | 2018-03-01 | 印度商托仁特生技有限公司 | 取代稠合嘧啶酮化合物 |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
CN108503648B (zh) * | 2018-04-27 | 2020-04-14 | 安徽医科大学 | 苯乙烯基吡唑并嘧啶类化合物、药物组合物及制备方法与用途 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN110015985B (zh) * | 2019-05-16 | 2022-05-13 | 河南师范大学 | 2-(α-氘-α-羟基-α-芳基/烷基)氮杂芳烃类化合物及其制备方法和应用 |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
BR112022025012A2 (pt) | 2020-06-08 | 2023-02-14 | Halia Therapeutics Inc | Inibidores de quinase de nek7 |
KR20230175222A (ko) | 2021-04-05 | 2023-12-29 | 할리아 테라퓨틱스, 인코포레이티드 | Nek7 억제제 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
US4966846A (en) * | 1987-10-01 | 1990-10-30 | W. R. Grace & Co.-Conn. | Molecular cloning and expression of a vibrio proteolyticus neutral protease gene |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
CA2078214C (en) | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
RU2155187C2 (ru) | 1992-08-06 | 2000-08-27 | Варнер-Ламберт Компани | Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека. |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
UA54427C2 (uk) | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
CA2253608A1 (en) | 1996-05-01 | 1997-11-06 | Louis Vignati | Therapeutic treatment for vegf related diseases |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
JP4876239B2 (ja) | 1999-01-11 | 2012-02-15 | プリンストン ユニバーシティー | 標的確認のための高親和性阻害剤およびその使用 |
SK3812002A3 (en) * | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
-
2002
- 2002-03-21 MX MXPA03008560A patent/MXPA03008560A/es active IP Right Grant
- 2002-03-22 BR BR0205890-1A patent/BR0205890A/pt not_active IP Right Cessation
- 2002-03-22 HU HU0400267A patent/HUP0400267A2/hu unknown
- 2002-03-22 JP JP2002576244A patent/JP4319412B2/ja not_active Expired - Fee Related
- 2002-03-22 IL IL15764002A patent/IL157640A0/xx unknown
- 2002-03-22 SK SK1312-2003A patent/SK13122003A3/sk not_active Application Discontinuation
- 2002-03-22 CN CNA028103149A patent/CN101426792A/zh active Pending
- 2002-03-22 CZ CZ20032837A patent/CZ20032837A3/cs unknown
- 2002-03-22 UY UY27222A patent/UY27222A1/es not_active Application Discontinuation
- 2002-03-22 EP EP02728546A patent/EP1379528A4/en not_active Withdrawn
- 2002-03-22 PL PL02363946A patent/PL363946A1/xx not_active Application Discontinuation
- 2002-03-22 PE PE2002000222A patent/PE20030047A1/es not_active Application Discontinuation
- 2002-03-22 KR KR10-2003-7012350A patent/KR20030088114A/ko not_active Application Discontinuation
- 2002-03-22 WO PCT/US2002/008996 patent/WO2002076986A1/en not_active Application Discontinuation
- 2002-03-22 CA CA2440714A patent/CA2440714C/en not_active Expired - Fee Related
- 2002-07-19 US US10/104,140 patent/US7332497B2/en not_active Expired - Fee Related
-
2003
- 2003-09-03 ZA ZA200306887A patent/ZA200306887B/en unknown
- 2003-09-19 NO NO20034177A patent/NO20034177L/no not_active Application Discontinuation
- 2003-09-19 EC EC2003004773A patent/ECSP034773A/es unknown
- 2003-09-22 CO CO03084062A patent/CO5570669A2/es not_active Application Discontinuation
- 2003-10-14 BG BG108268A patent/BG108268A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002076986A1 (en) | 2002-10-03 |
BR0205890A (pt) | 2004-06-29 |
PE20030047A1 (es) | 2003-02-07 |
US20040006083A1 (en) | 2004-01-08 |
EP1379528A1 (en) | 2004-01-14 |
NO20034177L (no) | 2003-11-21 |
JP2005501811A (ja) | 2005-01-20 |
IL157640A0 (en) | 2004-03-28 |
CZ20032837A3 (cs) | 2004-01-14 |
PL363946A1 (en) | 2004-11-29 |
UY27222A1 (es) | 2002-10-31 |
NO20034177D0 (no) | 2003-09-19 |
CA2440714C (en) | 2010-08-10 |
KR20030088114A (ko) | 2003-11-17 |
HUP0400267A2 (hu) | 2004-08-30 |
SK13122003A3 (sk) | 2004-04-06 |
US7332497B2 (en) | 2008-02-19 |
CA2440714A1 (en) | 2002-10-03 |
JP4319412B2 (ja) | 2009-08-26 |
MXPA03008560A (es) | 2004-06-30 |
CN101426792A (zh) | 2009-05-06 |
EP1379528A4 (en) | 2005-12-07 |
ZA200306887B (en) | 2004-09-13 |
CO5570669A2 (es) | 2005-10-31 |
ECSP034773A (es) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
DE60112974D1 (en) | Carbolinderivate | |
DE60216233D1 (en) | Carbolinderivate | |
JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
RS99203A (xx) | Pirolopirimidini kao inhibitori protein kinaza | |
MXPA03002911A (es) | Compuestos quimicos. | |
AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
MXPA03010761A (es) | Combinaciones farmaceuticas. | |
MXPA02012076A (es) | Compuestos quimicos. | |
MXPA02012659A (es) | Derivados de pirazindiona condensados. | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
TW200508199A (en) | Novel compound | |
MXPA03002909A (es) | Compuestos quimicos. | |
AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
MXPA03003971A (es) | Derivados de indol como inhibidores de pde5. | |
ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate | |
CA2445620A1 (en) | Tetracyclic compounds as pde5-inhibitors | |
MY136138A (en) | Hexacyclic compounds |